Alliances
Futura Medical plc is pleased to announce a joint venture collaboration with CBDerma Technology Limited to explore the application of Futura’s advanced proprietary transdermal drug delivery technology, DermaSys® for delivery of Cannabidiol.
Soricimed Biopharma Inc. announced that it has entered into a strategic alliance with Image Analysis Group, a UK-based company with unique expertise in medical imaging and artificial intelligence-based image analytics, whereby the companies will join their efforts in the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.
Case Western Reserve University and Boston-based Akouos have entered into an exclusive licensing agreement to develop a patented gene therapy with the potential to treat hearing loss associated with a type of Usher syndrome, the most common deaf-blind disorder.
The importance of artificial intelligence and machine learning is ever-increasing in the world of drug development and AstraZeneca is bolstering its participation in the tech revolution by striking a deal with New York-based Schrodinger to use that company’s advanced computing platform to help accelerate drug discovery efforts.
Theragnostics announces a licence agreement with AstraZeneca for intellectual property (IP) that enables Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi Polymerase inhibitors) with an option to an exclusive licence for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi.
The companies will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.
True Diagnostics, Inc. and Veravas announced their Strategic Alliance in the commercialization of VeraTest Biotin, a portable and easy-to-use digital qualitative test that can rapidly screen patient samples to determine if significant biotin is present, helping safeguard against potential biotin interference.
Motif Bio plc announces that its lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019.
Financial terms of the collaboration were not disclosed but shareholders of the Pennsylvania-based company responded favorably.
Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate.
PRESS RELEASES